Efficacy of bevacizumab plus bolus irinotecan, fluorouracil and leucovorin (IFL-BV) for highly pretreated metastatic colorectal cancer (MCRC)

被引：0
|
作者：
Carrera, S.
Munoz, A.
Gil-Negrete, A.
Rubio, I
Ancizar, N.
Calvo, B.
Fuente, N.
Barcelo, R.
Janhi, M.
Lopez-Vivanco, G.
机构：
[1] Hosp Cruces, Dept Med Oncol, Baracaldo, Spain
[2] Hosp Cruces, Mol Biol Lab, Baracaldo, Spain
来源：
ANNALS OF ONCOLOGY | 2006年 / 17卷
关键词：
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：68 / 68
页数：1
相关论文
共 50 条
  • [1] Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer
    Hurwitz, H
    Fehrenbacher, L
    Novotny, W
    Cartwright, T
    Hainsworth, J
    Heim, W
    Berlin, J
    Baron, A
    Griffing, S
    Holmgren, E
    Ferrara, N
    Fyfe, G
    Rogers, B
    Ross, R
    Kabbinavar, F
    NEW ENGLAND JOURNAL OF MEDICINE, 2004, 350 (23): : 2335 - 2342
  • [2] 5-FLUOROURACIL, LEUCOVORIN AND IRINOTECAN (FOLFIRI) PLUS BEVACIZUMAB (BV) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): A MULTICENTER PHASE II TRIAL
    Cordio, S.
    Parra, Soto H. J.
    Pumo, V
    Condorelli, S.
    Latteri, F.
    Sambataro, D.
    Rosati, G.
    Aprile, G.
    Fassari, G.
    De Pauli, F.
    Rimassa, L.
    Bordonaro, R.
    ANNALS OF ONCOLOGY, 2009, 20
  • [3] Panitumumab therapy with irinotecan, 5-fluorouracil, and leucovorin (IFL) in patients (pts) with metastatic colorectal cancer (mCRC)
    Berlin, Jordan
    Malik, Imtiaz
    Picus, Joel
    Glisson, Shawn
    Kozloff, Mark
    Spitzer, Gary
    Wiens, Brian
    MacDonald, Monica
    Jerian, Susan
    Hecht, J. Randolph
    ANNALS OF ONCOLOGY, 2004, 15 : 70 - 71
  • [4] Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
    Erlichman, C
    Goldberg, RM
    O'Connell, MJ
    NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (04): : 305 - 305
  • [5] Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer
    Krieger, G
    STRAHLENTHERAPIE UND ONKOLOGIE, 2001, 177 (06) : 316 - 318
  • [6] Quality of life (QoL) impact of bevacizumab (BV) when combined with irinotecan+5-FU/leucovorin (IFL) and 5-FU/leucovorin (FL) for metastatic colorectal cancer (mCRC).
    Chawla, A
    Holmgren, E
    Nelson, B
    Cella, D
    Yost, K
    Hurwitz, H
    Novotny, W
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 262S - 262S
  • [7] Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer.
    Saltz, LB
    Cox, JV
    Blanke, C
    Rosen, LS
    Fehrenbacher, L
    Moore, MJ
    Maroun, JA
    Ackland, SP
    Locker, PK
    Pirotta, N
    Elfring, GL
    Miller, LL
    NEW ENGLAND JOURNAL OF MEDICINE, 2000, 343 (13): : 905 - 914
  • [8] Oxaliplatin reintroduction in patients pretreated with leucovorin, fluorouracil and oxaliplatin for metastatic colorectal cancer (MCRC).
    Maindrault-Goebel, F
    Louvet, C
    André, T
    Carola, E
    Gilles, V
    Garcia, M
    Lotz, JP
    Izrael, V
    Krulik, M
    de Gramont, A
    ANNALS OF ONCOLOGY, 2000, 11 : 50 - 50
  • [9] OUR EXPERIENCE WITH IRINOTECAN AND BOLUS FLUOROURACIL/LEUCOVORIN IN THE TREATMENT OF PATIENTS WITH METASTATIC COLORECTAL CANCER
    Davidov, Deyan
    JOURNAL OF IMAB, 2009, 15 (01): : 49 - 52
  • [10] THE BUDGETARY IMPACT OF GENETIC-GUIDED DOSING OF 5-FLUOROURACIL, IRINOTECAN, LEUCOVORIN, AND BEVACIZUMAB (FOLFIRI plus BEV) IN METASTATIC COLORECTAL CANCER (MCRC)
    Rivers, Z.
    Stenehjem, D.
    Jacobson, P.
    Lou, E.
    Nelson, A.
    Kuntz, K. M.
    VALUE IN HEALTH, 2020, 23 : S42 - S42
12345